Regeneron Pharmaceuticals Operating Income 2010-2024 | REGN
Regeneron Pharmaceuticals operating income for the twelve months ending September 30, 2024 was $3.973B, a 5.87% decline year-over-year.
- Regeneron Pharmaceuticals annual operating income for 2023 was $4.047B, a 14.6% decline from 2022.
- Regeneron Pharmaceuticals annual operating income for 2022 was $4.739B, a 47.03% decline from 2021.
- Regeneron Pharmaceuticals annual operating income for 2021 was $8.947B, a 150.15% increase from 2020.